Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.00
(
1.15%
)
US TECH 100
23,529.60
(
0.04%
)
Dow Jones
46,208.47
(
1.38%
)
Brent Oil
98.29
(
1.54%
)
Bitcoin
71,173.00
(
0.39%
)
News Focus
News Focus
Post# of 257273
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 208547

Monday, 01/30/2017 10:35:59 AM

Monday, January 30, 2017 10:35:59 AM

Post# of 257273

The bane of modest financial resources combined with modest efficacy.

You're quite right. OCRX will not go anywhere with the IV formulation of OCR-002 if they can't do better than HR=0.80 vs placebo. The company's task now is to get the dose up to the point where the efficacy is clinically meaningful. The AE profile suggests that this is an achievable goal.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today